[Federal Register Volume 69, Number 167 (Monday, August 30, 2004)]
[Notices]
[Pages 52905-52906]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 04-19702]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Government-owned Inventions; Availability for Licensing and
Cooperative Research and Development Agreements (CRADAs)
AGENCY: National Institute for Occupational Safety and Health, Centers
for Disease Control and Prevention, Technology Transfer Office,
Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention named in this notice is owned by agencies of the
United States Government and is available for licensing in the United
States (U.S.) in accordance with 35 U.S.C. 207, and is available for
cooperative research and development agreements (CRADAs) in accordance
with 15 U.S.C. 3710, to achieve expeditious commercialization of
results of federally funded research and development. U.S. and foreign
patent applications are expected to be filed in the near future, to
extend market coverage for U.S. companies, and may also be available
for licensing.
ADDRESSES: Licensing information may be obtained by writing to Suzanne
Seavello Shope, J.D., Technology Licensing and Marketing Scientist,
Technology Transfer Office, Centers for Disease Control and Prevention
(CDC), Mailstop K-79, 4770 Buford Highway, Atlanta, GA 30341, telephone
(770) 488-8613; facsimile (770) 488-8615; e-mail sshope@cdc.gov. CRADA
information, and information related to the technology listed below,
may be obtained by writing to Kathleen Goedel, Program Analyst,
Technology Transfer Office, National Institute for Occupational Safety
and Health (NIOSH), Centers for Disease Control and Prevention (CDC),
mailstop R-6, 4676 Columbia Parkway, Cincinnati, OH 45226, telephone
(513) 841-4560; facsimile (513) 458-7170; or e-mail kgoedel@cdc.gov. A
signed Confidential Disclosure Agreement (available under Forms at
http://www.cdc.gov/tto) will be required to receive copies of
unpublished patent applications and other information.
Occupational Safety
Cleansing and Removal Method and Technique for Lead Contaminated Dermal
Surfaces
Workplace exposure to toxic metals, (i.e., lead, cadmium, and
arsenic) can cause systemic poisoning and are a recognized health
threat to thousands of workers in numerous industries. A potentially
significant, but often overlooked risk for exposures is hand-to-mouth
transfer due to contaminated hands. Other metals of concern include
chromium and nickel, which are potential skin sensitizers that can have
significant and long-term health consequences for those affected.
Prevention of skin exposures should be the primary course of action,
but effective removal of metals from skin becomes necessary when dermal
exposures cannot be completely controlled, and when the efficacy of
handwashing is questionable.
NIOSH/CDC researchers have developed a novel handwipe system for
removal of certain toxic metals from the skin. Preliminary research
shows that this new approach is highly effective and performs better
than traditional handwashing (soap and water) as well as better than
other commercial
[[Page 52906]]
handwashing products. The new method is easy to use and inherently safe
to both the user and the environment and has been submitted for patent
protection.
CDC/NIOSH is soliciting for a Cooperative Research and Development
Agreement (CRADA) partner to refine development of this new skin
cleanser and to license and commercialize the final product. Preferred
partners will have the ability to conduct testing to verify the safety
of regular repeated use through a battery of clinical and instrumental
test procedures aimed at determining skin compatibility. Testing trials
to assess user acceptance and laboratory evaluations to determine
product stability are also requested. Preferred partners should also be
able to propose recommendations to the basic formulation for
enhancements to user acceptance and final packaging of the end product.
Preferred partners will have a strong market share and a demonstrated
business network capable of effective dissemination of the final
product.
Patent applications will be filed on new intellectual property
resulting from the CRADA. The CRADA partner will have an option to
exclusively license any rights NIOSH/CDC may have in the new
technology.
Inventors: Esswein, Eric et al.
U.S. Patent Application SN: Not yet filed. (CDC Ref. : I-028-
03).
Dated: August 23, 2004.
James D. Seligman,
Associate Director for Program Service, Centers for Disease Control and
Prevention.
[FR Doc. 04-19702 Filed 8-27-04; 8:45 am]
BILLING CODE 4163-18-P